10th Annual Course on the BBB in Drug Development 2019 (Uppsala, Sweden)
October 2-4, 2019
The course is a coproduction of In Focus and Udenaes Consulting:
Elizabeth de Lange
Margareta Hammarlund-Udenaes is a Professor in Pharmacokinetics and Pharmacodynamics at Uppsala University, head of the Translational PKPD Group, and Dean of the Faculty of Pharmacy in Uppsala. Her research is focused at studying pharmacokinetic aspects of BBB transport of drugs in relation to CNS effects, which has led to the development of new concepts within the BBB transport area, focusing on unbound drug relationships. The concepts make it possible to study the BBB contribution to drug transport to the CNS. A method frequently used is microdialysis, but also PET and other techniques are utilized. Her research group has also optimized in vitro methods for more rapid screening of BBB transport properties in drug discovery. They also study nanodelivery to the brain. Dr Hammarlund-Udenaes is an Associate Editor of Pharmaceutical Research and a member of the Editorial Advisory Board of Journal of Pharmaceutical Sciences and Fluids and Barriers of the Central Nervous System (FBCNS). She became an AAPS Fellow in 2005 and is a frequent lecturer at conferences and in drug industry within the BBB transport – pharmacokinetics area. She co-founded and has co-chaired several of the International Symposia on Microdialysis in Drug Research and Development together with Dr de Lange. She was the Chair of the Gordon Conference on Barriers of the CNS in 2014. Her company Udenaes Consulting (email@example.com) gives advice to drug industry in PKPD and BBB transport issues.
Elizabeth de Lange is heading the Quantitative and Translational Pharmacology Research Group at the Research Division of Systems Biomedicine and Pharmacology at the Leiden Academic Centre of Drug Research. She obtained her PhD on The Use of Microdialysis to Study BBB Transport Characteristics of Drugs. Her group’s research involves the identification and characterization of the context dependency of the rate and extent of key factors in the dose-response relationship of CNS drugs in health and CNS disorders, with the ultimate aim being to aid in the prediction CNS drug effects in the clinical setting (translational research). As a highlight, recently a comprehensive CNS physiology-based pharmacokinetic model has been developed that is able to adequately predict drug concentration profiles in multiple CNS compartments in human. She co-founded and has co-chaired several of the International Symposia on Microdialysis in Drug Research and Development together with Dr Hammarlund-Udenaes, and organized many other scientific events among which the 2014 Annual Meeting of the American Association of Pharmaceutical Scientists (AAPS). She is an AAPS Fellow since 2013. She is a frequently invited lecturer. Her company In Focus provides courses, training and gives advice on pharmacokinetics, BBB transport, (CNS) target site distribution, binding kinetics and effects (PKPD) (firstname.lastname@example.org).